Brokerages Set CureVac N.V. (NASDAQ:CVAC) PT at $6.83

CureVac N.V. (NASDAQ:CVAC) has received a consensus rating of “Hold” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $6.8333.

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of CureVac in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On CureVac

A number of hedge funds have recently modified their holdings of CVAC. Alpine Associates Management Inc. boosted its stake in CureVac by 16.4% during the third quarter. Alpine Associates Management Inc. now owns 2,295,422 shares of the company’s stock worth $12,372,000 after buying an additional 324,247 shares during the period. Millennium Management LLC increased its holdings in CureVac by 10.3% in the first quarter. Millennium Management LLC now owns 1,816,984 shares of the company’s stock valued at $5,033,000 after buying an additional 169,947 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in shares of CureVac by 44.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,712,737 shares of the company’s stock worth $9,232,000 after buying an additional 530,686 shares during the last quarter. AQR Arbitrage LLC boosted its stake in CureVac by 2,145.7% in the third quarter. AQR Arbitrage LLC now owns 991,688 shares of the company’s stock valued at $5,345,000 after acquiring an additional 947,529 shares in the last quarter. Finally, Water Island Capital LLC purchased a new position in shares of CureVac during the second quarter worth about $5,197,000. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Stock Up 1.6%

CureVac stock opened at $5.11 on Friday. The business’s 50-day moving average price is $5.33 and its 200 day moving average price is $5.17. The company has a quick ratio of 6.16, a current ratio of 6.17 and a debt-to-equity ratio of 0.05. CureVac has a 52 week low of $2.47 and a 52 week high of $5.72. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of 5.32 and a beta of 2.56.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings results on Monday, November 24th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. CureVac had a return on equity of 29.57% and a net margin of 38.21%. As a group, sell-side analysts anticipate that CureVac will post 0.72 earnings per share for the current year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.